Kimberly-Clark announced the launch of Depend Guards and Shields, two products specifically designed for men with light bladder leakage, along with tips and tools from former professional football star Tony Siragusa in a new program called Guard Your Manhood

The Food and Drug Administration has approved a new use for a cancer drug made by Johnson & Johnson, the agency said Monday.

In a randomized trial that included nearly 15,000 male physicians and started in 1997, long-term daily multivitamin use resulted in a modest, but statistically significant, reduction in cancer after more than a decade of treatment and follow-up, according to a study appearing in JAMA that was released Wednesday.

Drug maker OncoGenex Pharmaceuticals has started its third late-stage clinical trial of a drug for treating a type of lung cancer.

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

A large new observational study published Friday found more evidence of an association between daily aspirin use and modestly lower cancer mortality, but suggested any reduction may be smaller than that observed in a recent analysis. The study appeared online in the Journal of the National Cancer Institute.

Safeway has raised more than $9 million during its month-long prostate cancer awareness campaign.

Safeway and its charitable arm have launched their annual prostate cancer awareness campaign this month.

All men know: It’s not the fall that kills you; it’s that sudden stop at the end. Men smoke more, drink more and eat more. Men die sooner and are less likely to seek health care on their own. Men are full-throttle all-systems-go, until one day they’re not. Because it’s that sudden run-in with a heart attack or stroke, that sudden diagnosis of prostate or colon cancers, that slows them down.

Evidence supporting the daily use of aspirin to help prevent and possibly treat cancer was published Tuesday in a collection of three papers — two in The Lancet and one in Lancet Oncology.

A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.

A drug made by Eli Lilly & Co. produced "significant" improvements in patients with erectile dysfunction who also had benign prostatic hyperplasia, according to results of a new study.